Journals / Uluslararası Hematoloji-Onkoloji Dergisi / 2016 / Cilt: 26 - Sayı: 3

Tedavi Öncesi Yüksek D-Dimer Düzeylerinin Venöz Tromboembolisi Olmayan Non-Metastatik Meme Kanserli

The Prognostic Value of High Pretreatment Plasma D-Dimer Levels in Non-Metastatic Breast Cancer Patients with Absence of Venous Thromboembolism

Pages
136–144
DOI
—
🏛️Bibliographic metadata and full text access for this article are provided via DergiPark.
DergiPark Record ↗
✨

AI Summary & Key Takeaways

AI Insight
⚡ TL;DR(Too Long; Didn't Read)

We aimed to investigate the prognostic value of DD in patients with non metestatic breast cancer (nMBC) and evaluated the DD levels and other variables for overall survival (OS) using univariate and multivariate analyses in 448 patients.

📌 3 Key Takeaways

🎯
Objective & Hypothesis:Systemic activation of coagulation and fibrinolysis is frequently observed in cancer patients without thrombosis.
📊
Key Findings & Data:We aimed to investigate the prognostic value of DD in patients with non metestatic breast cancer (nMBC) and evaluated the DD levels and other variables for overall survival (OS) using univariate and multivariate analyses in 448 patients.
💡
Conclusion & Impact:In conclusion, pretreatment high DD level is an important prognostic factor in patients with non metastatic breast cancer and high DD levels were associated with poor outcome.
🔬Design:Research Article
📍Scope:Comprehensive Sample
⚙️Variables:Domain Parameters

Abstract

Systemic activation of coagulation and fibrinolysis is frequently observed in cancer patients without thrombosis. Recent studies have showed the association between D-Dimer (DD) and metastatic spread and prognosis of cancer. We aimed to investigate the prognostic value of DD in patients with non metestatic breast cancer (nMBC) and evaluated the DD levels and other variables for overall survival (OS) using univariate and multivariate analyses in 448 patients. The median follow-up time was 50 months (3-151 months). There was only significant relationship between DD and distant metastases (p= 0.052). Performance status (PS) (p< 0.001 and < 0.001), stage (p< 0.001 and < 0.001) , CEA (p< 0.001 and < 0.001), CA 15-3 (p< 0.001 and < 0.001) and DD (p< 0.001 and 0.034) were determined as prognostic factors for OS in univariate analysis. In multivariate analysis, PS (ECOG 0 vs ECOG 1, p= 0.022; ECOG 0 vs ECOG >=2, (p< 0.001), stage (stage I vs stage II, p= 0.566; stage I vs stage III, p= 0.033), the CA 15-3 (p= 0.048) and DD levels (p= 0.015) were determined as independent prognostic factors for OS . In conclusion, pretreatment high DD level is an important prognostic factor in patients with non metastatic breast cancer and high DD levels were associated with poor outcome.

Özet

Hastalardaki Prognostik ÖnemiKoagülasyon ve fibrinolizin sistemik aktivasyonu sıklıkla tromboz olmayan kanser hastalarında gözlenir. Son yıllarda yapılan çalışmalar, D-Dimer (DD) ve metastatik yayılım ve kanser prognoz arasındaki ilişkiyi göstermiştir. Biz non-metastatik meme kanseri (nMBC) olan hastalarda DD prognostik değerini araştırmayı amaçladık. D-Dimer düzeyleri, genel sağkalımı (OS) etkileyebilecek diğer değişkenler, 448 hastada tek değişkenli ve çok değişkenli kullanarak değerlendirildi. Ortalama takip süresi 58.46 ± 1.8 ay idi. Sadece DD ile uzak metastaz (p= 0.052) arasındaki anlamlı bir ilişki saptandı. Performans durumu (PS) (p = 2 ve yüksek (p< 0.001), evre (Evre I vs evre II, s vs = 0.566; evre I vs evre III, p= 0.033), Ca15,3 (p= 0.048) ve DD düzeyleri (p= 0.015) Os için bağımsız risk faktörleri olarak belirlendi. Sonuç olarak, tedavi öncesi yüksek DD düzeyleri nMBC olan hastarada önemli bir prognostik faktördür ve kötü prognoz ile ilişkilidir.

🔖

Cite This Article

KAÇAN, T., YÜCEL, B., BAHAR, S., CELASUN, G., SEKER, M. M., BABACAN, N., BAHCECI, A., KACAN, S. B., KILIÇKAP, S. (2016). Tedavi Öncesi Yüksek D-Dimer Düzeylerinin Venöz Tromboembolisi Olmayan Non-Metastatik Meme Kanserli. Uluslararası Hematoloji-Onkoloji Dergisi, Cilt: 26 - Sayı: 3, 136–144. https://ajindex.com/articles/322837

📄 Full Text PDF Viewer

📄

PDF görüntüleyici hazırlanıyor...

References (13)

  1. Cabuk D, Basaran G, Teomete M, et al. Clinical outcome of Turkish metastatic breast cancer patients with currently avail- able treatment modalities--single center experience. Asian Pac J Cancer Prev 15: 117-122, 2014.
  2. Blackwell K, Haroon Z, Broadwater G, et al. Plasma D-dimer levels in operable breast cancer patients correlate with clinical stage and axillary lymph node status. J Clin Oncol 18: 600- 608, 2000.
  3. Ay C, Dunkler D, Pirker R, et al. High D-dimer levels are asso- ciated with poor prognosis in cancer patients. Haematologica 97: 1158-1164, 2012.
  4. Knowlson L, Bacchu S, Paneesha S, et al. Elevated D-dimers are also a marker of underlying malignancy and increased mortality in the absence of venous thromboembolism. J Clin Pathol 63: 818-822, 2010.
  5. Rickles FR, Edwards RL. Activation of blood coagulation in cancer: Trousseau's syndrome revisited. Blood 62: 14-31, 1983.
  6. Dvorak HF, Brown LF, Detmar M, et al. Vascular permeability factor/vascular endothelial growth factor, microvascular hy- perpermeability, and angiogenesis. Am J Pathol 146: 1029- 1039, 1995. Di Castelnuovo A, de Curtis A, Costanzo S, et al. Association of D-dimer levels with all-cause mortality in a healthy adult population: findings from the MOLI-SANI study. Haemato- logica 98: 1476-1480, 2013.
  7. Altiay G, Ciftci A, Demir M, et al. High plasma D-dimer level is associated with decreased survival in patients with lung cancer. Clin Oncol (R Coll Radiol) 19: 494-498, 2007.
  8. Yamamoto M, Yoshinaga K, Matsuyama A, et al. Plasma Ddimer level as a mortality predictor in patients with advanced or recurrent colorectal cancer. Oncology 83: 10-15, 2012.
  9. Nagy Z, Horvath O, Kadas J, et al. D-dimer as a potential prognostic marker. Pathol Oncol Res 18: 669-674, 2012. Nagy Z. Biomarkers in solid tumors. Magy Onkol 57: 56-62, 2013.
  10. Lorenzet R, Donati MB. Blood clotting activation, angiogenesis and tumor metastasis: any role for TFPI? Thromb Haemost 87: 928-929, 2002.
  11. Mielicki WP, Tenderenda M, Rutkowski P, et al. Activation of blood coagulation and the activity of cancer procoagulant (EC 3.4.22.26) in breast cancer patients. Cancer Lett 146: 61-66, 1999.
  12. Dirix LY, Salgado R, Weytjens R, et al. Plasma fibrin D-dimer levels correlate with tumour volume, progression rate and survival in patients with metastatic breast cancer. Br J Cancer 86: 389-395, 2002.
  13. Yigit E, Gonullu G, Yucel I, et al. Relation between hemostatic parameters and prognostic/predictive factors in breast cancer. Eur J Intern Med 19: 602-607, 20